plaque brachytherapy: Definition, Uses, and Clinical Overview

plaque brachytherapy Introduction (What it is)

plaque brachytherapy is a type of internal radiation treatment used to treat certain eye tumors.
A small “plaque” containing a radiation source is temporarily placed on the outside of the eye near the tumor.
It is most commonly used in ocular oncology, especially for tumors arising inside the eye.

Why plaque brachytherapy used (Purpose / benefits)

The main purpose of plaque brachytherapy is to deliver a controlled dose of radiation to a targeted area inside the eye while limiting exposure to surrounding tissues. In general terms, it aims to treat or control a tumor by damaging the DNA of tumor cells, reducing their ability to divide and survive.

In eye care, the problem plaque brachytherapy is designed to solve is local tumor control within a small, delicate organ where wide surgical removal can be vision-threatening or require removal of the eye. For selected intraocular tumors, it is used with the goal of:

• Treating the tumor in place (rather than removing the eye in situations where eye-preserving treatment is possible).
• Concentrating radiation where it is needed most, which can be important when the tumor is near critical structures such as the macula (central retina) or optic nerve.
• Offering a localized approach that typically avoids full-field external beam radiation to the entire orbit.

Potential benefits vary by clinician and case, but commonly discussed advantages include eye preservation, a defined treatment course (often days rather than weeks), and the ability to tailor plaque size and positioning to tumor location.

Indications (When ophthalmologists or optometrists use it)

plaque brachytherapy is typically considered when an eye specialist (often an ophthalmic oncologist) diagnoses or strongly suspects an intraocular tumor that may respond to localized radiation. Common scenarios include:

• Choroidal melanoma (a melanoma arising from the uvea, usually the choroid)
• Ciliary body melanoma
• Selected iris melanomas
• Some cases of retinoblastoma (often as part of a multi-treatment strategy; varies by center)
• Some choroidal metastases (tumors spread from elsewhere in the body), when local control is needed
• Selected vascular tumors such as circumscribed choroidal hemangioma (case selection varies)
• Recurrent or residual tumor after other local treatments, when further local control is needed

Optometrists may not perform plaque brachytherapy, but they may help detect suspicious lesions during routine exams and participate in long-term surveillance for vision changes and radiation-related complications.

Contraindications / when it’s NOT ideal

plaque brachytherapy is not suitable for every tumor or every patient. Situations where it may be less ideal, not feasible, or where another approach may be preferred include:

• Tumors that are too large for safe or effective plaque coverage (size thresholds vary by clinician and case)
• Tumors with extensive extraocular extension (growth outside the eye), where plaque placement may not adequately treat all involved tissue
• Diffuse tumors with poorly defined margins, making targeted dosing and coverage difficult
• Tumors in locations where adequate plaque placement is technically challenging (for example, very close to the optic nerve may require specialized plaque designs; feasibility varies)
• Eyes with very limited visual potential from other causes, where the goals of eye preservation versus comfort and disease control may differ
• Medical factors that make anesthesia or surgery higher risk (assessment varies by clinician and patient health)
• Situations where another radiation modality (such as proton beam therapy) may better match tumor geometry or spare specific structures, depending on local availability and expertise

“Not ideal” does not mean “never used.” Treatment selection is individualized, and different centers may have different protocols and experience.

How it works (Mechanism / physiology)

Core mechanism (radiation effect):
plaque brachytherapy uses ionizing radiation to damage cellular DNA. Tumor cells that are actively dividing are generally less able to repair this damage, which can reduce tumor growth and lead to tumor regression over time. The goal is typically local tumor control, not an immediate “removal” of the mass.

What the “plaque” is:
A plaque is a small, curved device (often metal-backed) that is sutured to the sclera (the white outer wall of the eye) over the tumor base. The plaque holds one or more radiation sources (commonly radioactive “seeds” or a radioactive layer), positioned so the highest dose is delivered toward the tumor.

Relevant eye anatomy:

• Sclera: where the plaque is attached externally.
• Uvea (choroid, ciliary body, iris): common origin site for melanomas treated with plaques.
• Retina and macula: light-sensing tissue and central vision area that may be affected by radiation depending on proximity.
• Optic nerve: carries visual signals to the brain and is sensitive to radiation exposure.
• Lens: may develop radiation-associated cataract if exposed.

Onset and duration:
The radiation is delivered while the plaque is in place, often for a defined period such as several days (exact timing varies by isotope, prescribed dose, and planning). Tumor response is typically gradual and monitored over months to years with examinations and imaging.

Reversibility:
The plaque itself is temporary and removed after treatment. However, radiation effects in tissue are not “reversible” in the way a medication can be stopped; some side effects may improve, while others can be lasting. The balance between tumor control and radiation exposure to normal tissue is a key part of treatment planning.

plaque brachytherapy Procedure overview (How it’s applied)

plaque brachytherapy is a treatment procedure that involves both planning and surgical placement. The exact workflow varies by center, but a general overview often includes:

1. Evaluation / exam
   – Detailed eye examination (often including dilated fundus exam).
   – Imaging to document tumor size and location, such as ocular ultrasound, fundus photography, and sometimes OCT (optical coherence tomography).
   – Assessment for tumor features and staging workup as appropriate (the broader medical evaluation depends on diagnosis).

2. Preparation
   – Tumor measurements are used to choose plaque size and design.
   – A radiation plan is created, often involving a medical physicist, to estimate dose delivery to the tumor and nearby structures.
   – Discussion of expected course and follow-up schedule (details vary by clinician and case).

3. Intervention (plaque placement)
   – The plaque is surgically sutured to the sclera overlying the tumor.
   – Placement aims to align the plaque so the radiation field covers the tumor with an appropriate margin (planning methods vary).

4. Immediate checks
   – Confirmation of plaque position (methods vary by center).
   – Instructions about radiation safety precautions while the plaque is in place (recommendations vary by isotope and institutional policy).

5. Plaque removal and follow-up
   – After the prescribed treatment time, the plaque is removed in a second procedure.
   – Follow-up visits monitor tumor response, vision, and potential radiation-related effects over time.

This overview is intentionally high level; specific steps, timing, and safety protocols differ across institutions and individual cases.

Types / variations

plaque brachytherapy is not one single standardized device or dose plan. Common variations include differences in radiation source, plaque design, and planning approach.

By radiation source (examples):

• Iodine-125 (I-125) seeds: commonly used for posterior uveal tumors in many centers.
• Ruthenium-106 (Ru-106): used in some regions; penetration characteristics differ from I-125.
• Palladium-103 (Pd-103): used in some centers; dose distribution differs.
• Other sources may be used depending on availability, regulations, and clinician preference (varies by material and manufacturer).

By plaque construction and shielding:

• Many plaques use a high-density backing (often gold) to help shield radiation away from the orbit and direct it toward the eye.
• Seed arrangement, collimation, and plaque thickness can vary by design.

By plaque shape and special designs:

• Standard circular plaques for many choroidal tumors.
• Notched plaques designed to fit closer to the optic nerve when tumors are juxtapapillary (right next to the nerve).
• Custom plaques for unusual tumor geometry or location (availability varies).

By clinical intent and context:

• Primary treatment for a newly diagnosed tumor.
• Salvage treatment for recurrent or persistent disease after another local therapy (case selection varies).
• Adjunctive use in multi-modality care for certain tumor types.

Pros and cons

Pros:

• Can provide localized radiation targeted to the tumor area
• Often supports eye preservation in selected cases
• Treatment duration is typically finite and planned (often days for plaque placement, with long-term follow-up)
• Radiation exposure to the rest of the body is generally limited compared with systemic therapies
• Plaque size and positioning can be tailored to tumor location and dimensions (varies by case)
• Can be used for tumors in different intraocular locations with appropriate plaque design
• Long-term monitoring allows clinicians to track tumor regression and manage complications over time

Cons:

• Radiation can affect nearby healthy tissues, potentially impacting vision (risk depends on tumor location and dose distribution)
• Possible complications include radiation retinopathy, radiation optic neuropathy, cataract, and dry eye symptoms (likelihood varies)
• Requires surgery for placement and a second procedure for removal
• Follow-up is long-term and typically includes repeated imaging and examinations
• Not all tumors are suitable (for example, very large or diffuse tumors may not be ideal candidates)
• Local tumor control does not eliminate the need for systemic evaluation in diseases where spread is a concern (depends on diagnosis)
• Emotional and practical burden of a cancer-directed treatment course can be significant for some patients

Aftercare & longevity

After plaque brachytherapy, follow-up focuses on two broad goals: monitoring the tumor response and detecting/managing radiation-related eye changes.

Outcomes and “longevity” of results depend on multiple factors, including:

• Tumor type, size, and location: Tumors closer to the macula or optic nerve may carry a higher risk of vision-affecting side effects because these tissues are sensitive to radiation.
• Dose planning and plaque positioning: Small differences in geometry can change which tissues receive more radiation.
• Baseline vision and other eye conditions: Pre-existing macular disease, glaucoma, diabetic retinopathy, or cataract can influence visual outcomes.
• Systemic health and comorbidities: Conditions affecting blood vessels (such as diabetes or hypertension) may influence retinal vulnerability, though individual risk varies.
• Follow-up consistency: Regular visits help clinicians identify changes early, document tumor regression, and address complications in a timely way (specific schedules vary by clinician and case).
• Device/material choice: The isotope, plaque design, and manufacturer-specific characteristics can affect dose distribution and practical handling (varies by material and manufacturer).

Many changes after radiation are gradual. Tumor shrinkage or scarring patterns are typically assessed over months to years, and vision changes can also evolve over time.

Alternatives / comparisons

plaque brachytherapy is one option within a broader set of treatments for intraocular tumors. The most appropriate comparison depends on diagnosis, tumor dimensions, location, and patient factors.

Common alternatives or related approaches include:

• Observation / monitoring:
  Some small or indeterminate lesions may be monitored for growth or risk features before treatment. This approach prioritizes careful documentation and timely intervention if the lesion changes.

• Enucleation (surgical removal of the eye):
  May be considered for very large tumors, painful blind eyes, or when eye-preserving therapy is not feasible or not expected to provide meaningful visual function. The trade-offs differ substantially from plaque brachytherapy and are individualized.

• External beam radiation therapies (including proton beam therapy):
  These approaches deliver radiation from outside the body rather than via a plaque. They can be useful for certain tumor shapes or locations and may be preferred in some centers depending on equipment and expertise.

• Local tumor ablation techniques (laser or heat-based):
  Options such as transpupillary thermotherapy or laser-based treatments may be considered for selected small lesions or as adjuncts. Suitability varies by tumor type and evidence base.

• Local resection or biopsy-driven approaches:
  In selected cases, partial surgical removal or diagnostic biopsy may be part of management. These approaches have different risk profiles and goals.

• Systemic therapy (medications):
  For metastatic disease or specific tumor biology, systemic treatments may be considered in coordination with oncology. These address disease beyond the eye and are not direct substitutes for local tumor control.

A key difference is that plaque brachytherapy is typically a localized, eye-directed treatment aimed at controlling a defined tumor area, whereas some alternatives prioritize broader-field radiation, surgical removal, or systemic disease control.

plaque brachytherapy Common questions (FAQ)

Q: Is plaque brachytherapy painful?
Discomfort varies by person and by the specifics of plaque placement. The procedures are performed with anesthesia, and soreness or irritation can occur afterward. Pain levels and symptom patterns vary by clinician and case.

Q: How long does the plaque stay on the eye?
The plaque is temporary and is removed after the planned dose has been delivered. This is often on the order of days, but the exact duration depends on the radiation source, prescribed dose, and treatment plan. Your care team determines timing based on the individual plan.

Q: Will I lose vision after plaque brachytherapy?
Visual outcomes vary widely and depend strongly on tumor location and which sensitive structures receive radiation. Some people maintain useful vision, while others experience gradual vision decline from radiation effects or from the tumor itself. Clinicians monitor vision and retinal health over time.

Q: Is plaque brachytherapy considered “safe”?
It is a widely used, established treatment in ocular oncology, but it still involves radiation and surgery, so risks exist. Safety is managed through dose planning, shielding, and follow-up monitoring. The risk–benefit balance is individualized.

Q: Will I be radioactive, and can I be around family?
While the plaque is in place, there is a radiation source near the eye, so centers provide specific safety instructions. Policies differ by isotope and institution, and recommendations may include limits on close contact for certain periods. After the plaque is removed, radiation precautions are generally reduced or no longer needed.

Q: What is the recovery like after placement and removal?
Recovery commonly includes a period of eye irritation, redness, or sensitivity, with gradual improvement over days to weeks. Vision may be blurry temporarily from inflammation or other factors. Longer-term recovery is more about monitoring delayed radiation effects than healing from the procedures themselves.

Q: Can I drive or use screens after plaque brachytherapy?
Whether driving is appropriate depends on vision in the treated and fellow eye, comfort, and any activity restrictions from the treating center. Screen use is usually limited by irritation, light sensitivity, or temporary blur rather than the radiation itself. Activity guidance varies by clinician and case.

Q: How long do results last?
The treatment is intended to provide durable local tumor control, but the timeline of tumor regression and the durability of control vary by diagnosis and tumor characteristics. Follow-up is long-term because both recurrence and radiation effects can occur later. Your care team uses imaging and exams to track stability.

Q: Does plaque brachytherapy cure eye cancer?
The term “cure” depends on tumor type and whether disease is confined to the eye. Plaque brachytherapy is primarily a local treatment aimed at controlling the eye tumor. For conditions with a risk of spread, systemic evaluation and long-term surveillance are typically part of care.

Q: How much does plaque brachytherapy cost?
Cost varies by country, hospital system, insurer, isotope, operating room needs, and follow-up requirements. It may include expenses for planning, surgery, the plaque/radioactive source, facility fees, and multiple follow-up visits. A care team or billing office can explain typical cost components for a specific setting.